The enormous demographic shift has had a profound impact on the future structure and course of the Saudi healthcare system.
Since there are chances and prospects in developing regions like APAC, LATAM, the Middle East, and Africa, many medical device companies have focused their efforts there.
Manufacturers, distributors, and investors see Saudi Arabia as a promising market since it has the largest economy in the MENA area.
The industry’s present potential is a result of the expanding healthcare sector and government backing for domestic production.
Utilizing the local value chain, this new strategy will advance to value-added MedTech products driven by local and regional demand.
The Saudi Arabia Medical Devices Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Gulf Medical Company is chosen by Provation to be it’s only partner in Saudi Arabia for its industry-leading clinical productivity solution.
Gulf Medical Company, Ltd., a global leader in the distribution of medical devices and software, has announced an exclusive agreement with Provation, the leading software supplier of procedural documentation and clinical decision support systems.
The collaboration deal enables Gulf Medical to market and distribute Provation MD, the world’s leading software for documenting gastrointestinal (GI) and respiratory procedures, across the Kingdom of Saudi Arabia (KSA).
In addition to replacing paper clinical documentation, Provation MD connects with current hospital information systems to enhance procedure notes’ uniformity, accuracy, and efficiency.
Due to Gulf Medical’s stellar reputation and solid business ties with both the private and public hospital sectors in the region, Provation awarded it the partnership.
In order to localise the medical device business and transfer medical technology to Saudi Arabia, the Saudi Made pavilion, which is taking part in the Arab Health Exhibition in Dubai, United Arab Emirates, has welcomed the signing of a cooperative agreement.
The Al-Dawaa Medical Services Company (DMSCO) and a number of foreign businesses from well-known nations boasting of medical sectors inked the cooperation agreement.
The CEO of DMSCO also inked a deal with three businesses from China, Spain, and Finland in the areas of medical manufacturing, technical solutions, and healthcare.
The fact that the medical gadgets will be produced in the DMSCO plant in Sudair City for Industry and Businesses, which is regarded as one of the most cutting-edge factories in its category in Saudi Arabia, is notable.
The deal was reached to assist “Saudi Made,” a project of the National Industrial Development and Logistics Program and one of the initiatives of the Saudi Export Development Authority (NIDLP)
Johnson & Johnson Medical Saudi Arabia Limited was established by Johnson & Johnson Medical Devices Companies (JJMD).
It is a Saudi Arabian-registered legal entity that is the result of a partnership between Farouk Maamoun Tamer & Co., Abdulrehman Algosaibi, and Johnson & Johnson Middle East FZ-LLC. The company’s main objective is to develop healthcare solutions for the nation.
During the COVID-19 outbreak, healthcare costs rose, which led to the introduction of numerous digital health applications.
Citizens reported being unable to order medications or personal medical equipment online and experiencing a lack of individualised care through digital health applications, even as lawmakers defended their stance on expanding access to and quality of health care services.
Moreover, there are differences in how accessible, used, and perceived digital health technologies are depending on the population group.
Digital health technologies are being quickly used in Saudi Arabia to manage healthcare operations and enhance service and delivery quality.
As a result, there have been significantly fewer COVID-19 instances in the kingdom; nonetheless, there has been no discernible decrease in the number of COVID-related deaths.
This may suggest that Saudi Arabia has been successful in implementing mitigation techniques to stop the spread of the virus, but less successful in addressing the effects of COVID-19 on people’s health and healthcare operations.
For instance, fewer doctors are choosing to use telemedicine, improper management of the workload, and stress among healthcare professionals are only a few of the problems that demonstrate the inefficiency of the tactics used.
The COVID-19 pandemic has significantly disrupted the world’s pharmaceutical supply chain, but its effects were well under control in Saudi healthcare facilities.
This can be attributed to a number of factors, including the successful hospital exchange programs and the sharp rise in public healthcare spending to lessen the pandemic’s negative effects on the healthcare industry.
© Copyright 2017-2023. Mobility Foresights. All Rights Reserved.